Stephen Knowles

Stephen Knowles has a diverse work experience in the healthcare and pharmaceutical industry. Stephen currently serves as the Chief Medical Officer at Halozyme Therapeutics, Inc., a position they assumed in February 2020. Prior to this role, they were the Vice President of Drug Safety & Pharmacovigilance at the same company from January 2018 to February 2020.

Before joining Halozyme Therapeutics, Inc., Stephen worked extensively at Eli Lilly and Company. From June 2013 to December 2017, they held the position of Senior Director of GPS Medical & Benefit Risk Management. Stephen also served as the Senior Director of Risk Management and Pharmacoepidemiology from February 2013 to May 2013. In addition, they held various other roles at Eli Lilly and Company, such as Senior Director of Global Patient Safety for Endocrine and Autoimmune, Senior Director of Global Patient Safety for Neuroscience, and Director of Global Clinical Trial Case Management Operations.

Prior to their time at Eli Lilly and Company, Stephen worked at Eli Lilly as a Lead CRP (Clinical Research Physician) in the areas of Oncology and Neuroscience. Stephen also held the position of Head of Patient Safety for the UK & Ireland region. Stephen'sexperience at Eli Lilly spanned from 2001 to 2005.

Stephen's career started in 1984 as a Practising Physician in the UK National Health Service. Stephen practiced medicine until September 2001.

Overall, Stephen Knowles has a strong background in medical leadership, drug safety, pharmacovigilance, risk management, and clinical research.

Stephen Knowles attended Newcastle University from 1979 to 1984, where they earned their MBBS degree. The field of study for their degree is not provided.